WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion
WuXi AppTec (Shanghai) Co., Ltd., a wholly‑owned subsidiary of Wuxi AppTec Co., Ltd. (SHA: 603259,...
Wuxi Apptec Reports 15.3 % YoY Revenue Growth in Q3 2025, Net Profit Hits RMB 4.22 Billion
Wuxi Apptec Co., Ltd. (SHA: 603259, HKG: 2359) today announced third‑quarter 2025 financial results, delivering...
Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that...
Novartis Strikes USD 12b Deal for Avidity’s RNA Therapeutics and Gene-Targeted Pipeline
Novartis (NYSE: NVS) announced an agreement to acquire San Diego-based biotech Avidity Biosciences for USD...
Eli Lilly to Acquire Adverum Biotechnologies for Up to USD 261.7m for Ixo-vec Access
Eli Lilly (NYSE: LLY) announced on October 24, 2025, that it will acquire gene therapy...
Alphamab Oncology’s JSKN003 Approved for Phase III Trial in HER2-Positive CRC
Alphamab Oncology (HKG: 9966), a China-based biotechnology company, announced on October 27, 2025, that its...
AstraZeneca Launches Sixth Global R&D Center in Beijing to Accelerate China Investments
AstraZeneca (AZ, NASDAQ: AZN) announced on October 25, 2025, the launch of its sixth Global...
Chiesi Group Launches First EB Wound Treatment in China
The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative...
Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio
Chugai Pharmaceutical, a member of the Roche Group, announced on October 24, 2025, that it...
Innovent’s Mazdutide Meets Phase III Endpoint in Type 2 Diabetes and Obesity Trial
Innovent Biologics (HKG: 1801) announced on October 27, 2025, that its fourth Phase III clinical...
Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&D Programs
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a China-based company, released its 2025 third-quarter...
Astellas Establishes First China Innovation R&D Center in Beijing BioPark
Astellas Pharma (TYO: 4503) announced on October 27, 2025, the establishment of its first China...
Novartis Transfers Lucentis and Beovu Rights to CMS Vision in China Deal
Novartis (NYSE: NVS) announced on October 27, 2025, the signing of a strategic cooperation agreement...
GSK Secures Global Rights to Syndivia’s ADC for Metastatic Prostate Cancer
British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that...
Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia
Chongqing Zhifei Biological Co., Ltd’s (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received...
LEO Pharma Submits NDA for Anzupgo in China for Chronic Hand Eczema
LEO Pharma announced on October 17, 2025, that it has submitted a New Drug Application...
Eli Lilly Partners with Cipla to Distribute New Tirzepatide Brand “Yurpeak” in India
Eli Lilly and Company (India) Pvt. Ltd. (Lilly) and Cipla Limited (BOM: 500087, NSE: CIPLA) today announced a...
Alphamab Announces First Patient Dosed with JSKN022, a PD‑L1/αvβ6 Bispecific ADC
China‑based Alphamab Oncology (HKG: 9966) today announced that the first patient received a dose of...
Hansoh Pharmaceutical Submits HS‑10365 NDA to NMPA for RET‑Positive NSCLC
China‑based Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced today that it has filed a New Drug Application...
Jiangsu Hengrui Secures NMPA Approval to Launch Phase III Trial of Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the National...